NCT06650644已完成不适用
A Multicenter, Randomized, Double-blind, Placebo-controlled, Investigator-initiated Human Study to Evaluate the Efficacy and Safety of Lactococcus Lactis KD10 Powder in Improving Autism Spectrum Symptoms in Pediatric Patients With Autism Spectrum Disorder.
Miae Oh4 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2024年10月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 4
- 主要终点
- Change rate of major symptoms of autism spectrum disorder (%)_Korean version of Vineland Adaptive Behavior Scale-II(K-VABS-II)
研究概览
简要总结
This human study aims to evaluate the efficacy and safety of Lactococcus lactis KD10 powder for improving autism spectrum disorder symptoms in patients with autism spectrum disorder.
详细描述
The purpose of this human study is to confirm the change rate (%) in the main symptoms of autism spectrum disorder after 12 weeks of taking Lactococcus lactis KD10 powder in subjects with autism spectrum disorder.
In addition, we will conduct tests using various evaluation scales at the 12-week point to evaluate the degree of autism spectrum disorder symptoms and coexisting disease symptoms, and to evaluate the overall safety during the human study period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 36 Months 至 91 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Children aged 3 years or older and 7 years and 7 months or younger
- •Those diagnosed with autism spectrum disorder through a standardized diagnostic tool according to the diagnostic criteria for autism spectrum disorder in the DSM-5 (Diagnostic and Statistical Manual of Mental disorder-5) at the time of screening [Diagnostic tool: Korean version of Autism Diagnostic Observation Schedule version 2 (K-ADOS-2), Korean version of Autism Diagnostic Interview-Revised (K-ADI-R)] (However, if diagnosed with autism spectrum disorder through a diagnostic evaluation within 6 months of screening, only the K-ADOS-2 test will be re-evaluated.)
- •Those judged by the investigator on the day of screening to be able to consume the food for this human test (control food) without chewing it, with water or the provided puree
- •Those subjects or/and their legal representatives who voluntarily agreed to participate in this human test and signed a written consent form and a consent form for research on human-derived materials
- •A person who can provide reliable information on the condition of the test subject during the human test period, attend all planned visits to the institution, supervise the intake of food for human test, and have the participation of a parent or the same legal representative who can fully understand and speak Korean, and conduct a questionnaire evaluation of the subject.
排除标准
- •[Screening Visit (Visit 1)]
- •Those with the following medical history, concomitant diseases, or surgical history at the time of screening ① Severe psychosis that may affect this test other than autism spectrum disorder
- •② History of organic brain disease, neurological disorder, uncontrolled epilepsy, or seizures. However, simple febrile seizures can be included at the investigator's discretion
- •③ Genetic diseases (Rett syndrome, Down syndrome, Fragile X syndrome, etc.) However, participation is allowed at the investigator's discretion only if it is confirmed to be a genetic disease that does not affect the results of this test
- •④ Gastrointestinal diseases and surgical history that may affect the intestinal absorption of food for human testing (simple appendectomy, hernia surgery are allowed)
- •⑤ Those with sensory abnormalities such as congenital hearing loss
- •Those with uncontrolled medical conditions (including arrhythmia, cancer, severe heart/kidney disease) during the screening period
- •Those who exhibit serious self-harming or other-harming behaviors that require medical treatment at the investigator's discretion during the screening period
- •Those who have been confirmed to have taken the following drugs within 2 weeks prior to screening or are expected to take the following drugs during the human application test period. However, for drugs with a sufficient washout period exceeding 2 weeks, a washout period of at least 5 times the maximum half-life must be confirmed before the screening time.
- •① Antipsychotic drugs (antipsychotic, psychostimulant, antidepressant, anxiolytic, mood stabilizer, and neuroleptic agents). If there is no change in the type or dosage of the drug within 3 months of screening due to long-term use, participation is possible at the investigator's discretion
- •② Selective Serotonin Reuptake Inhibitor (SSRI)
- •Those with the following test results confirmed during screening
- •① Moderate or higher renal impairment (eGFR <60mL/min/1.73m2)
- •② Moderate or higher hepatic impairment(AST or ALT >3 x ULN)
- •Those who cannot receive intravenous injection for blood collection
- •Those who have difficulty consuming human application test food or are sensitive or allergic to human test food
- •Those who participated in other clinical trials or human trials within 4 weeks prior to screening and were administered or consumed clinical trial drugs or human test food or were applied with clinical trial medical devices
- •Those who are judged unsuitable for participation in human trials by the investigator
- •[baseline visit (Visit 2)]
- •Those with unsuitable items when reconfirming the selection/exclusion criteria at the time of randomization
- •Those judged unsuitable for participation in this human study by the investigator other than the above
结局指标
主要结局
Change rate of major symptoms of autism spectrum disorder (%)_Korean version of Vineland Adaptive Behavior Scale-II(K-VABS-II)
时间窗: Baseline(0 weeks), 12 weeks
To determine the change rate (%) in major symptoms of autism spectrum disorder
次要结局
- Social Skills Change Rate (%)_Korean version of Autism Diagnostic Observation Schedule version 2(K-ADOS-2)(Baseline(0 weeks), 12 weeks)
- Social Skills Change Rate (%)_Korean version of Childhood Autism Rating Scale-2(K-CARS-2)(Baseline(0 weeks), 12 weeks)
- Social Skills Change Rate (%)_Social Responsiveness Scale-2(SRS-2)(Baseline(0 weeks), 12 weeks)
- Social Skills Change Rate (%)_Korean version of Social Communication Questionnaire(K-SCQ)(Baseline(0 weeks), 12 weeks)
- Social Skills Change Rate (%)_Aberrant Behavior Checklist-II(Baseline(0 weeks), 12 weeks)
- Level of functioning Change Rate (%)_Korean version of Wechsler Primary and Preschool Scale Intelligence-Ⅳ(K-WPPSI-Ⅳ)(Baseline(0 weeks), 12 weeks)
- Level of functioning Change Rate (%)_CGI-S (Clinical Global Impression-Severity)(Baseline(0 weeks), 12 weeks)
- Level of functioning Change Rate (%)_CGI-I (Clinical Global Impression-Improvement)(12 weeks)
- Executive function Change Rate (%)_Children's Color Trail making Test 1&2(CCTT 1&2)(Baseline(0 weeks), 12 weeks)
- Executive function Change Rate (%)_Stroop Test (Color & word)(Baseline(0 weeks), 12 weeks)
- Executive function Change Rate (%)_ Advanced Test of Attention(ATA)(Baseline(0 weeks), 12 weeks)
- Executive function Change Rate (%)_Korean version of ADHD Rating Scale-IV(K-ARS-4)(Baseline(0 weeks), 12 weeks)
- Sleep disturbance Change Rate (%)_The Korean version of the Children's Sleep Habits Questionnaire(Baseline(0 weeks), 12 weeks)
- Anxiety Change Rate (%)_Korean version of Child Behavior Checklist (K-CBCL)(Baseline(0 weeks), 12 weeks)
- Anxiety Change Rate (%)_Korean form of the State and Trait Anxiety Inventory for Children (K-STAIC)(Baseline(0 weeks), 12 weeks)
- GI trouble Change Rate (%)_Profile Of Toileting Issue (POTI)(Baseline(0 weeks), 12 weeks)
- Sensory Change Rate (%)_Short Sensory Profile-2 (SSP-2)(Baseline(0 weeks), 12 weeks)
- Parenting stress change rate (%)_Korean version of Parenting Stress Index Forth edition-Short Form (K-PSI-4-SF)(Baseline(0 weeks), 12 weeks)
研究者
Miae Oh
Professor
Kyunghee University Medical Center
研究点 (4)
Loading locations...
相似试验
已完成
3 期
A Study of a Probiotic in Atopic DermatitisAtopic DermatitisNCT00893230Chungbuk National University88
终止
不适用
Effect of Consuming a Combination of Probiotic Strains on Postpartum DepressionPostpartum DepressionNCT06651424Biosearch S.A.5
终止
2 期
Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft SurgeryCoronary Artery Bypass SurgeryNCT00858936Mallinckrodt6
进行中（未招募）
3 期
Phase 3 Study of KP-100LI in Subjects With Vocal Fold ScarVocal Fold ScarNCT05627648Kringle Pharma, Inc.62
招募中
3 期
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Chronic Inflammatory Demyelinating PolyneuropathyNCT06752356Kedrion S.p.A.161